健康元NS-041片新增适应症临床试验获批

Core Viewpoint - The announcement highlights that Health元's subsidiary, Lijun Pharmaceutical Group, has received approval for clinical trials of NS-041 tablets for the treatment of depression, marking a significant development in the company's product pipeline [1] Group 1: Company Developments - Health元's subsidiary, Lijun Pharmaceutical Group, has received a clinical trial approval notice from the National Medical Products Administration for NS-041 tablets to include a new indication for the treatment of depression [1] - NS-041 tablets are a novel high-selectivity KCNQ2/3 agonist aimed at treating neurological and psychiatric disorders, specifically epilepsy and depression [1] - NS-041 is currently the only KCNQ2/3 targeted drug in China approved to conduct clinical research for both epilepsy and depression [1] Group 2: Clinical Trial Status - As of December 27, 2023, NS-041 tablets have also been approved to conduct clinical trials for the indication of epilepsy, which is currently undergoing Phase II clinical research [1]